Introduction {#S1}
============

Neuromyelitis optica spectrum disorder (NMOSD), an idiopathic inflammatory demyelinating disorder of the central nervous system that involves both the optica nerves and the spinal cord, was considered a subtype of multiple sclerosis (MS) for many years until the discovery of its specific serum antibody biomarker---aquaporin (AQP) 4 IgG ([@B1]--[@B3]). Although B cells, AQP-4 antibody-dependent complement-dependent cellular cytotoxicity (CDCC), and antibody-mediated cellular cytotoxicity (ADCC) play decisive roles in the pathogenesis of NMOSD, eosinophils have been implicated as an important player in the pathological lesions following blood--brain barrier (BBB) injury ([@B4]--[@B6]). The basic histopathological features of NMOSD have been described as acute spinal cord lesions with diffuse swelling and softening over multiple segments involving the entire spinal cord or having continuous distribution ([@B7]). Autopsy examination has shown that a prominent feature of human NMOSD lesions is markedly greater eosinophilic infiltration than that seen with other demyelinating diseases like MS ([@B8], [@B9]). Eosinophils are also found in the cerebrospinal fluid (CSF) of patients with NMOSD, and demyelinating NMOSD lesions show marked eosinophil infiltration in patients with NMOSD and mouse models ([@B4], [@B10]--[@B12]). Lesion severity can increase because of transgenic hyper-eosinophilia and *vice versa* ([@B4]). An interesting finding is the presence of eosinophils in inflammatory demyelinating lesions in NMOSD but their absence in MS. Further, eosinophils have been found in all early active NMOSD lesions but not in cases of acute disseminated encephalomyelitis or acute spinal cord infarction ([@B8]). Other studies have proved that the lesion infiltrates are associated with C--C motif chemokine receptor (CCR)-3 expression and stain positively for major basic protein (MBP) in eosinophils, suggesting basic protein release from granules in patients with NMOSD.

CCR3 is highly expressed on the surface of eosinophils. Interactions of CCR3 with a variety of chemokines including CCL11 (eotaxin-1), CCL24 (eotaxin-2), CCL26 (eotaxin-3), CCL13 (monocyte chemoattractant protein 4, MCP-4), CCL8 (MCP-2), and CCL7 (MCP-3) play an important role in the migration, accumulation, and activation of eosinophils ([@B13]--[@B15]). The "eotaxins," CCL11, CCL24, and CCL26, represent selective chemoattractants for eosinophils ([@B14]). Together with CCL11, CCL13 is one of the most important eosinophilic chemoattractants ([@B16]). This protein homeostatically recruits eosinophils to organs in disease states. In humans, four MCPs have been identified: MCP-1 (CCL2), MCP-2 (CCL8), MCP-3 (CCL7), and MCP-4 (CCL13) ([@B17]). Unlike other MCPs, CCL13 binds not only with CCR1 and CCR2 but also with CCR3, to act as a chemoattractant for eosinophils ([@B18], [@B19]). Several lines of evidence have shown that CCL13 plays a pivotal role in inflammatory cell recruitment in allergic and autoimmune disorders such as rheumatoid arthritis, asthma, parasitic infection, and atopic dermatitis, and it also works in overweight subjects ([@B20]--[@B24]).

The present study aimed to investigate the factors that induce the effects of eosinophils in NMOSD during remission. Thirty healthy controls (HC), 47 patients with MS, and 58 patients with NMOSD were enrolled to screen cytokines and chemokines. The study showed that plasma levels of tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, CCL13, CCL11, and CCL26 were increased in patients with NMOSD. Additional analysis led to the finding that CCL13 levels were strongly correlated with recurrence times, and we believe that it can be considered one of the most valuable prognostic factors in NMOSD.

Subjects and Methods {#S2}
====================

Subjects {#S2-1}
--------

Ethics approval for this study was obtained from the ethics committee of the Beijing Tiantan Hospital Affiliated to the Capital Medical University in China (No. KY2015-003-02). Prior to participation, all patients and HC provided written informed consent.

Patients with NMOSD and MS were recruited from the Beijing Tiantan Hospital between January 2016 and August 2017. The diagnosis of these conditions was confirmed according to the 2015 revised international criteria ([@B25]) and the 2010 McDonald's diagnostic criteria ([@B26]), respectively. All patients were in remission (had remained relapse-free for over a 1-month period) and were not coexisting any other autoimmune comorbidities at the time of blood collection. Kutzke Expand Disability Status Scale (EDSS) scores were determined from an MS cohort study. Age- and sex-matched volunteers without immune disorders were recruited as HC. Infections were ruled out on the basis of complete blood count testing in all subjects.

Assay for Plasma Chemokines and Cytokine Levels {#S2-2}
-----------------------------------------------

Peripheral blood was obtained from each subject. To exclude the effect of different time points and other factors on the level of chemokines and cytokines, all blood samples were collected at 9:00 a.m. After collection into a 4-ml disposable BD Vacutainer^®^ containing ethylene diamine tetraacetic acid, plasma samples were separated at 2,000 × *g* for 10 min within 3 h and stored in aliquots at −80°C until further analysis. All testing was performed in a blinded manner to the diagnosis or clinical presentations.

Plasma CCL11, CCL24, and CCL26; CCL2, CCL8, CCL7, and CCL13; and TNF-α and IL-1β levels were assayed using MILLIPLEX^®^ map human High Sensitivity Cytokine/Chemokine Panels (Cat. Nos. HCYTOMAG-60K and HCYP2MAG-62K) (Merck KGaA, Darmstadt, Germany) according to the manufacturer's instructions.

Statistical Analysis {#S2-3}
--------------------

Statistical analysis was conducted using SPSS 22.0 (International Business Machines Corporation, Chicago, IL, USA). After the test of normality, data with non-Gaussian distributions were analyzed using the Mann--Whitney *U*-test for two groups and the Kruskal--Wallis *H*-test for multiple groups by using Dunn's *post hoc* analysis. Normally distributed data were processed using Student's *t* test or analysis of variance. CCL13, CCL11, and CCL26 values of NMOSD patients were used as independent variables in multiple linear regression analysis, with relapse times, annual relapse rate (ARR), and EDSS scores as continuous outcome measure. Gender, age, body mass index (BMI), and duration of NMOSD were included to determine the variables independently associated with these outcomes. Correlations between TNF-α, IL-1β, and CCL13, CCL11, and CCL26 were assessed using nonparametric Spearman's rank test. A *P*-value of \<0.05 was considered to be statistically significant.

Results {#S3}
=======

Clinical Demographics {#S3-1}
---------------------

We identified 58 patients with NMOSD, 47 patients with MS, and 30 HC, and their demographic and clinical characteristics are described in Table [1](#T1){ref-type="table"}. The disease duration and duration to the last relapse in the patients with NMOSD were not significantly longer than that in patients with MS. A significant difference in EDSS scores was found between the NMOSD and MS groups (*P* \< 0.01), which was consistent with our previous findings ([@B27]).

###### 

Patient demographic and clinical characteristics.

  Index                                                    HC             MS              NMOSD
  -------------------------------------------------------- -------------- --------------- -----------------
  No. of patients                                          30             47              58
  Gender (female/male)                                     22/8           34/13           54/4
  Age (years, mean ± SE)                                   33.90 ± 1.64   34.96 ± 1.59    39.53 ± 1.57
  Age at onset (years, median, and range)                  --             30, 6--60       35, 14--62
  BMI (kg/m^2^, mean ± SE)                                 21.58 ± 0.44   22.36 ± 0.43    22.80 ± 0.42
  Duration of disease (months, mean, and range)            --             40.36, 1--143   56.11, 2--260
  Duration to the last relapse (months, mean, and range)   --             5.79, 1--57     5.91, 1--33
  No. of relapses (mean ± SE)                              --             2.85 ± 0.26     3.35 ± 0.23
  ARR (mean ± SE)                                          --             2.17 ± 0.37     1.62 ± 0.20
  EDSS                                                     --             2.64 ± 0.20     3.54 ± 0.21\*\*

*HC, healthy controls; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorders; No., number, BMI, body mass index; EDSS, expanded disability status scale; ARR, annual relapse rate*.

*\*\*P \< 0.01*.

Plasma MCPs (CCL2, CCL8, CCL7, and CCL13) and Eotaxins (CCL11, CCL24, and CCL26) Levels in NMOSD {#S3-2}
------------------------------------------------------------------------------------------------

Plasma CCL13 levels were significantly higher in patients with NMOSD than in HC and patients with MS. The levels in patients with MS were not significantly higher than in HC (Figure [1](#F1){ref-type="fig"}A). We also examined the levels of other MCPs in all subjects. Unlike CCL13, no significant differences were found in the levels of CCL2 and CCL8 among patients with NMOSD, patients with MS, and HC (Figures [1](#F1){ref-type="fig"}B,C). Further, the CCL7 levels in almost all subjects were below measurable levels (Figure [1](#F1){ref-type="fig"}D).

![Plasma levels of monocyte chemoattractant proteins (CCL13, CCL2, CCL8, and CCL7). **(A)** Plasma CCL13 levels in healthy control (HC), multiple sclerosis (MS) patients, and neuromyelitis optica spectrum disorder (NMOSD) patients (mean ± SE). **(B,C)** No significant differences of CCL2 and CCL8 levels were found among plasma in HC, MS patients, and NMOSD patients (mean ± SE) (*P* = 0.89 and 0.39, respectively). **(D)** Plasma CCL7 levels in almost all subjects were below measurable levels. Kruskal--Wallis *H*-test and Dunn's *post hoc* analysis were used. \**P* \< 0.05, \*\**P* \< 0.01.](fneur-09-00044-g001){#F1}

Plasma CCL11 levels in patients with NMOSD during remission were significantly higher than those in patients with MS and HC, and CCL26 levels showed similar findings. Patients with MS had higher CCL11 levels than the HCs did, but no significant differences were found in CCL26 levels between them (Figures [2](#F2){ref-type="fig"}A,C). No significant differences were found in plasma CCL24 levels among the three groups (Figure [2](#F2){ref-type="fig"}B). Similar results were found when removing the NMOSD outliers in CCL13, CCL11, and CCL26 concentrations and data were shown in Figure S3 in Supplementary Material.

![Plasma levels of eotaxins (CCL11, CCL24, and CCL26). **(A,C)** Different plasma levels of CCL11 and CCL26 levels in healthy control (HC), multiple sclerosis (MS) patients, and neuromyelitis optica spectrum disorder (NMOSD) patients (mean ± SE), and **(B)** no significant differences of CCL24 levels were found among the three groups (mean ± SE) (*P* = 0.18). Kruskal--Wallis *H*-test and Dunn's *post hoc* analysis were used. \**P* \< 0.05, \*\**P* \< 0.01.](fneur-09-00044-g002){#F2}

Effect of Immunosuppressive Therapy on Plasma Levels of CCL13, CCL11, and CCL26 in NMOSD {#S3-3}
----------------------------------------------------------------------------------------

Eighty-three percent of the recruited patients with NMOSD were undergoing immunosuppressive therapy \[*n* = 48; 27 with oral glucocorticoids and 21 with oral treatment with mycophenolate mofetil, azathioprine, tocilizumab, or cyclosporine A (14 patients received one of these drugs in combination with glucocorticoids)\]. Therefore, it was necessary to study whether immunosuppressive therapy affected plasma CCL13, CCL11, and CCL26 levels. The plasma CCL13, CCL11, and CCL26 levels in patients with and without immunosuppressive therapy were both significantly higher than those in the HC, and the levels in patients undergoing immunosuppressive therapy were not significantly lower than those in the other 10 patients (Figure S1 in Supplementary Material). These findings indicated that immunosuppressive therapy had little effect on the three eosinophilic chemoattractant levels.

Regression Analysis of CCL13, CCL11, and CCL26 with Relapse Times, ARR, and EDSS Scores in NMOSD {#S3-4}
------------------------------------------------------------------------------------------------

In NMOSD patients, multiple regression analysis of CCL13, CCL11, and CCL26 with relapse times, ARR, and EDSS scores showed that only CCL13 was significantly related to relapse times (*R^2^* = 0.553, *P* = 0.000) after controlling gender, age, BMI, and disease duration (Table [2](#T2){ref-type="table"}). Age and disease duration were identified as independent factors associated with relapse times (*P* = 0.029 and 0.024, respectively). Gender and BMI showed no independent and significant regression coefficient with relapse times (*P* = 0.158 and 0.355, respectively). No associations of CCL11, CCL13, and CCL26 with ARR or EDSS scores were found. These data suggested that plasma CCL13 levels may have a prognostic value in NMOSD. Further studies with a larger number of subjects would provide adequate power to detect the differential correlation pattern between CCL13 levels and the clinical characteristics of NMOSD. Similar results were found after removing the NMOSD outliers in CCL13, CCL11, and CCL26 concentrations (Table 1 in Supplementary Material).

###### 

Adjusted regression coefficients (β) of CCL13, CCL11, and CCL26 levels with relapse times, ARR, and EDSS scores as outcomes in neuromyelitis optica spectrum disorder patients.

  Chemokines   Outcomes        Adjusted β   *R*^2^   *P*-values         Adjusted for
  ------------ --------------- ------------ -------- ------------------ -----------------------
  CCL13        Relapse times   0.571        0.553    0.000              Age, disease duration
  ARR          0.002           0.331        0.985    Disease duration   
  EDSS         0.007           0.179        0.959    Age                
                                                                        
  CCL11        Relapse times   0.015        0.274    0.903              Age, disease duration
  ARR          −0.128          0.346        0.281    Disease duration   
  EDSS         0.051           0.181        0.700    Age                
                                                                        
  CCL26        Relapse times   −0.032       0.274    0.803              Age, disease duration
  ARR          0.017           0.331        0.891    Disease duration   
  EDSS         −0.031          0.180        0.820    Age                

*ARR, annual relapse rate; EDSS, expanded disability status scale*.

Plasma TNF-α and IL-1β Levels and Their Correlation with CCL13, CCL11, and CCL26 Levels {#S3-5}
---------------------------------------------------------------------------------------

In order to explore the mechanisms underlying the increased CCL13, CCL11, and CCL26 levels in NMOSD, we examined the levels of plasma TNF-α and IL-1β, which have been proposed to stimulate their production. The data showed that both plasma TNF-α and IL-1β levels in patients with NMOSD were significantly higher than those in HC. Further, the TNF-α levels were lower in patients with MS than in those with NMOSD (Figures [3](#F3){ref-type="fig"}A,B). Plasma TNF-α and IL-1β levels were positively correlated with plasma CCL13, and TNF-α levels were also positively correlated with plasma CCL11 levels (Figure S2 in Supplementary Material). No correlation was found between IL-1β and CCL11 (*P* = 0.299), and neither TNF-α nor IL-1β levels showed correlations with CCL26 (*P* = 0.108 and 0.297, respectively).

![**(A,B)** Plasma levels of tumor necrosis factor-alpha (TNF-α) and interleukin-1β (IL-lβ) in healthy control (HC), multiple sclerosis (MS) patients, and neuromyelitis optica spectrum disorder (NMOSD) patients. Kruskal--Wallis *H*-test and Dunn's *post hoc* analysis were used. \**P* \< 0.05, \*\**P* \< 0.01.](fneur-09-00044-g003){#F3}

Discussion {#S4}
==========

Recently available data suggest that low-grade inflammation plays a pivotal role in the development of NMOSD, and low-grade inflammation is frequently observed in patients with NMOSD. As a source of versatile proinflammatory mediators, eosinophils have the unique characteristic-specific granules, which contain four major granule proteins (MBP, eosinophil cationic protein, eosinophil peroxidase, and eosinophil neurotoxin) and numerous cytokines, chemokines, and growth factors ([@B28]). These granule releases are the involved infiltrates of eosinophilic ADCC and CDCC response. Histopathologic studies had demonstrated that marked perivascular and meningeal eosinophil infiltrations were showed in active NMOSD lesions and were associated with CCR3 expression ([@B8]). CCR3 is a member of the seven transmembrane domain G protein-coupled receptor family, and its major ligands---CCL13 and eotaxins (CCL11, CCL24, and CCL26)---are involved in eosinophil chemoattraction ([@B29]).

Similar to other MCPs, CCL13 binds to CCR1 and CCR2 and acts as a chemoattractant for monocytes, T cells, and dendritic cells (DCs), and it is the only MCP that binds to CCR3. Together with CCL11, CCL13 is one of the most important chemoattractants for eosinophils ([@B16]). Considering the roles that eosinophils play in NMOSD pathogenesis, CCL13 may act as a distinctive chemoattractant in NMOSD. Compared to other MCPs, CCL13 plays an interesting role in DC migration into inflamed lesions, because monocytes and blood DC precursors such as CD34+-derived DCs and CD11c + DCs respond first to CCR2 ligands and CCL13 in epithelial cells present in contracted blood vessels, and these cells could then be recruited into inflamed tissue by a different gradient ([@B30], [@B31]). In addition, one subtype of Th17 cells that could induce the production of the AQP-4 antibody is distinguishable from its expression of CCR2 + CCR5− and RORγt, and ligands of CCR2 like CCL13 may be important regulators in the recruitment of Th17 cells in NMOSD pathogenesis ([@B32]). In the present study, we demonstrated for the first time that the level of the MCP-4 protein is elevated in the sera of patients with NMOSD. This elevation may in turn activate DCs and Th17 cells, especially eosinophils, which could worsen inflammation and lead to recurrence ([@B33]). In addition, the association of CCL13 levels with the number of relapses was analyzed, and the results showed a significant positive relationship between them. This finding indicated that CCL13 may play an extensive pathological role during remission in NMOSD. On the basis of these findings, we suggest that blocking the actions of CCL13 might serve as a novel strategy for the generation of agents with anti-inflammatory activity during remission in patients with NMOSD.

Other MCPs that bind with CCR1 and CCR2 to achieve signal cascade were also assayed in the present study. The results showed no significant changes in CCL2 and CCL7 levels during remission in patients with NMOSD. Further, the CCL7 levels were too low to measure in most patients, which is in line with the findings of most studies ([@B34]).

Several studies identified higher levels of eotaxins in the CSF and serum of patients with NMOSD than those in MS patients during acute attacks and concluded that this may be responsible for eosinophil migration across the BBB ([@B10], [@B35]); however, few studies focus on eotaxins levels during remission. The present study showed that plasma CCL11 and CCL26 were upregulated in patients with NMOSD during remission, implying that CCL11 and CCL26 may persistently participate in eosinophil activation, recruitment, and amplification in the pathogenesis of NMOSD after acute attacks. However, CCL24, which is also a strong chemoattractant for eosinophils, was not upregulated during the remission stage. Furthermore, no correlation was found between CCL11 levels, as well as CCL26, and clinical characteristics of patients with NMOSD.

Moreover, TNF-α and IL-1β were examined in this study for their ability to stimulate the release of multiple cytokines including CCL13 and eotaxins through the extracellular signal-regulated kinase cascade ([@B18], [@B36]--[@B40]). The results showed that the levels of both these inflammatory markers were elevated in the plasma of patients with NMOSD during remission. This indicated that TNF-α and IL-1β may be involved in the pathogenesis NMOSD mediated by CCL13, CCL11, and CCL26.

Collectively, the findings of the present study indicated that CCL13, CCL11, and CCL26 were upregulated by TNF-α and IL-1β, and this in turn led to the activation of eosinophils. This may have worsened the inflammation, leading to relapses in patients with NMOSD during remission.
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